← Back to patent-cliff list
Cotsiranib
Tier C — Watch / tradeCotsiranib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：COX-2, TGF-β1
Indications (approved)：Stroke, 基底鳞状细胞癌, 瘢痕疙瘩, Basal cell carcinoma, 腹部肥胖, Liver cancer, Cholangiocarcinoma, Hepatocellular carcinoma
Regional status
US
Phase II
2017-01-01
EU
-
China
Unspecified clinical stage
2017-04-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cotsiranib?
Approved indications include: Stroke, 基底鳞状细胞癌, 瘢痕疙瘩, Basal cell carcinoma, 腹部肥胖, Liver cancer, Cholangiocarcinoma, Hepatocellular carcinoma.
When does the Cotsiranib patent expire?
No public expiry year is available for Cotsiranib yet; this page updates once verified.
How do I get a quote for Cotsiranib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09